Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

M. Wagner, Lars; Fouladi, Maryam; Ahmed, Atif; Krailo, Mark; J. Weigel, Brenda; G. DuBois, Steven; Austin Doyle, L.; Chen, Helen; M. Blaney, Susan

doi:10.1002/pbc.25334

Public

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

Published in Pediatric Blood & Cancer • Nov 28, 2014

Authors:

Lars M. Wagner

Maryam Fouladi

Atif Ahmed

Abstract

BACKGROUND: The combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mammalian target of rapamycin (mTOR) has shown activity in preclinical models of pediatric sarcoma and in adult sarcoma patients. We evaluated the activity of the anti-IGF-1R antibody cixutumumab with the m...

Subject

Temsirolimus

Medicine

Sarcoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!